Samjin Pharm (005500) - Total Liabilities

Latest as of September 2025: ₩184.63 Billion KRW ≈ $125.12 Million USD

Based on the latest financial reports, Samjin Pharm (005500) has total liabilities worth ₩184.63 Billion KRW (≈ $125.12 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Samjin Pharm (005500) net asset momentum to track the company's year-over-year net asset growth rate.

Samjin Pharm - Total Liabilities Trend (2013–2024)

This chart illustrates how Samjin Pharm's total liabilities have evolved over time, based on quarterly financial data. See Samjin Pharm free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.

Samjin Pharm Competitors by Total Liabilities

The table below lists competitors of Samjin Pharm ranked by their total liabilities.

Company Country Total Liabilities
Nordic Halibut AS
OL:NOHAL
Norway Nkr556.32 Million
Chia Chang Co Ltd
TW:4942
Taiwan NT$2.30 Billion
South Logistics JSC
VN:STG
Vietnam ₫1.05 Trillion
UPDATER SERVICES LIMITED
NSE:UDS
India Rs5.84 Billion
PHA Co. Ltd
KQ:043370
Korea ₩278.28 Billion
São Carlos Empreendimentos e Participações S.A
SA:SCAR3
Brazil R$1.79 Billion
SHIMAO SERV.HLDGS HD-01
F:5GO
Germany €5.44 Billion
Assertio Therapeutics Inc
NASDAQ:ASRT
USA $135.67 Million

Liability Composition Analysis (2013–2024)

This chart breaks down Samjin Pharm's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Samjin Pharm market cap and net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.25 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.70 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.41 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Samjin Pharm's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Samjin Pharm (2013–2024)

The table below shows the annual total liabilities of Samjin Pharm from 2013 to 2024.

Year Total Liabilities Change
2024-12-31 ₩163.51 Billion
≈ $110.81 Million
+5.81%
2023-12-31 ₩154.54 Billion
≈ $104.73 Million
+18.24%
2022-12-31 ₩130.69 Billion
≈ $88.57 Million
+32.92%
2021-12-31 ₩98.33 Billion
≈ $66.64 Million
+76.92%
2020-12-31 ₩55.58 Billion
≈ $37.66 Million
+19.07%
2019-12-31 ₩46.68 Billion
≈ $31.63 Million
+3.84%
2018-12-31 ₩44.95 Billion
≈ $30.46 Million
-7.09%
2017-12-31 ₩48.38 Billion
≈ $32.79 Million
-16.41%
2016-12-31 ₩57.88 Billion
≈ $39.22 Million
-20.36%
2015-12-31 ₩72.67 Billion
≈ $49.25 Million
-12.72%
2014-12-31 ₩83.26 Billion
≈ $56.43 Million
-8.46%
2013-12-31 ₩90.96 Billion
≈ $61.64 Million
--

About Samjin Pharm

KO:005500 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$151.60 Million
₩223.70 Billion KRW
Market Cap Rank
#17623 Global
#717 in Korea
Share Price
₩18250.00
Change (1 day)
+2.24%
52-Week Range
₩17010.00 - ₩24700.00
All Time High
₩50479.08
About

Samjin Pharmaceuticals Co., Ltd. manufactures and sells medicine. It offers medicine in oral, drop, and injecting forms. The company provides over-the-counter medicines, such as Gevorin, an anti-infalammatory pain killer; Trestan, an appetite stimulant; Flaris, an anti-thrombotic agent; and Nutilin, a brain function improvement agent, as well as medicine for treatment of chronic diseases. It also… Read more